This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yoshimura, K. Articles by Schulick, R. D. Search for Related Content PubMed PubMed Citation Articles by Yoshimura, K. Articles by Schulick, R. D.

Live Attenuated Listeria Monocytogenes Effectively Treats Hepatic Colorectal Cancer Metastases and Is Strongly Enhanced by Depletion of Regulatory T Cells

¹ Department of Surgery and ² Immunology and Hematopoiesis Division, Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland and ³ Department of Immunology, University of Colorado Health Sciences Center, Denver, Colorado

Requests for reprints: Richard D. Schulick, Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD 21231. Phone: 410-614-9879; Fax: 410-614-9882; E-mail: rschulick{at}jhmi.edu.

The liver represents a major and frequently sole site of metastases for many types of cancer, particularly gastrointestinal cancers. We showed previously that coadministration of an engineered hepatic-targeting Listeria monocytogenes (LM) with a cancer vaccine enhanced the antitumor effect of vaccine-induced T cells selectively against hepatic metastases. Here, we show that administration of multiple doses of LM, in the absence of vaccine, generates therapeutic responses against hepatic metastases. LM treatment of mice bearing hepatic metastases induced tumor-specific CD8⁺ T-cell responses that were enhanced by depletion of regulatory T (Treg) cells by either anti-CD25 or cyclophosphamide treatment. Antitumor activity of LM further depended on natural killer (NK) cell activation but was inhibited by presence of a subset of NK T cells. These results show the utility of LM in the treatment of hepatic metastases even in the absence of vaccine administration and further suggest that blockade of Treg cells and NK T cells will enhance antitumor activity. [Cancer Res 2007;67(20):10058–66]

This article has been cited by other articles:

				K. Yoshimura, K. F. Meckel, L. S. Laird, C. Y. Chia, J.-J. Park, K. L. Olino, R. Tsunedomi, T. Harada, N. Iizuka, S. Hazama, et al. Integrin {alpha}2 Mediates Selective Metastasis to the Liver Cancer Res., September 15, 2009; 69(18): 7320 - 7328. [Abstract] [Full Text] [PDF]

				M. Kovar, J. Tomala, H. Chmelova, L. Kovar, T. Mrkvan, R. Joskova, Z. Zakostelska, T. Etrych, J. Strohalm, K. Ulbrich, et al. Overcoming Immunoescape Mechanisms of BCL1 Leukemia and Induction of CD8+ T-Cell-Mediated BCL1-Specific Resistance in Mice Cured by Targeted Polymer-Bound Doxorubicin Cancer Res., December 1, 2008; 68(23): 9875 - 9883. [Abstract] [Full Text] [PDF]